• Reference Citation Analysis
  • v
  • v
  • Find an Article
Find an Article PDF (4609580)   Today's Articles (213)   Subscriber (49378)
For: Mehta LK, Hobbs S, Chen S, Knox RJ, Parrick J. Phthalimide analogs of CB 1954: synthesis and bioactivation. Anticancer Drugs 1999;10:777-83. [PMID: 10573210 DOI: 10.1097/00001813-199909000-00011] [Citation(s) in RCA: 7] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/25/2022]
Number Cited by Other Article(s)
1
Cuff S, Lewis RD, Chinje E, Jaffar M, Knox R, Weeks I. An improved cell-permeable fluorogenic substrate as the basis for a highly sensitive test for NAD(P)H quinone oxidoreductase 1 (NQO1) in living cells. Free Radic Biol Med 2018;116:141-148. [PMID: 29325897 DOI: 10.1016/j.freeradbiomed.2018.01.009] [Citation(s) in RCA: 10] [Impact Index Per Article: 1.7] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 06/26/2017] [Revised: 01/02/2018] [Accepted: 01/06/2018] [Indexed: 11/23/2022]
2
Singleton DC, Li D, Bai SY, Syddall SP, Smaill JB, Shen Y, Denny WA, Wilson WR, Patterson AV. The nitroreductase prodrug SN 28343 enhances the potency of systemically administered armed oncolytic adenovirus ONYX-411NTR. Cancer Gene Ther 2007;14:953-67. [DOI: 10.1038/sj.cgt.7701088] [Citation(s) in RCA: 36] [Impact Index Per Article: 2.1] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/09/2022]
3
Knox RJ, Chen S. Quinone Reductase–Mediated Nitro-Reduction: Clinical Applications. Methods Enzymol 2004;382:194-221. [PMID: 15047103 DOI: 10.1016/s0076-6879(04)82011-1] [Citation(s) in RCA: 17] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/10/2023]
4
Newell DR, Searle KM, Westwood NB, Burtles SS. Professor Tom Connors and the development of novel cancer therapies by the Phase I/II Clinical Trials Committee of Cancer Research UK. Br J Cancer 2003;89:437-54. [PMID: 12888809 PMCID: PMC2394365 DOI: 10.1038/sj.bjc.6601106] [Citation(s) in RCA: 12] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/09/2022]  Open
5
Professor Tom Connors and the development of novel cancer therapies by the Phase I/II Clinical Trials Committee of Cancer Research UK. Br J Cancer 2003. [PMID: 12888809 DOI: 10.1038/sj.bjc.6601106+[doi]] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/08/2022]  Open
6
Newell DR, Searle KM, Westwood NB, Burtles SS. Professor Tom Connors and the development of novel cancer therapies by the Phase I/II Clinical Trials Committee of Cancer Research UK. Br J Cancer 2003. [DOI: 10.1038/sj.bjc.6601106 [doi]] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/09/2022]  Open
7
Ross D, Kepa JK, Winski SL, Beall HD, Anwar A, Siegel D. NAD(P)H:quinone oxidoreductase 1 (NQO1): chemoprotection, bioactivation, gene regulation and genetic polymorphisms. Chem Biol Interact 2000;129:77-97. [PMID: 11154736 DOI: 10.1016/s0009-2797(00)00199-x] [Citation(s) in RCA: 457] [Impact Index Per Article: 19.0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/01/2023]
PrevPage 1 of 1 1Next
© 2004-2024 Baishideng Publishing Group Inc. All rights reserved. 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA